These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Absence of prostacyclin involvement in angiotensin-induced aldosterone secretion in rat adrenal cells. Campbell WB; Gomez-Sanchez CE Endocrinology; 1985 Jul; 117(1):279-86. PubMed ID: 3924581 [TBL] [Abstract][Full Text] [Related]
8. Prostanoid synthesis by aortic rings in human blood: selective increase of prostacyclin mediated by a serum factor. Ritter JM Br J Pharmacol; 1984 Oct; 83(2):409-18. PubMed ID: 6386089 [TBL] [Abstract][Full Text] [Related]
9. A comparison of the effects of prostacyclin and 6-keto-prostaglandin E1 on renin release in the isolated rat and rabbit kidney. Schwertschlag U; Stahl T; Hackenthal E Prostaglandins; 1982 Jan; 23(1):129-38. PubMed ID: 7038776 [TBL] [Abstract][Full Text] [Related]
10. Evidence for 6-keto-PGF1 alpha in adrenal cortex of the rat and effects of 6-keto-PGF1 alpha and PGI2 on adrenal cAMP levels and steroidogenesis. Laychock SG; Walker L Prostaglandins; 1979 Nov; 18(5):793-811. PubMed ID: 232283 [TBL] [Abstract][Full Text] [Related]
11. Effects of prostacyclin (PGI2), 6-oxo-PGF1 alpha and PGE2 on sympathetic nerve function in mesenteric arteries and veins of the rabbit in vitro. Armstrong JM; Thirsk G; Salmon JA Hypertension; 1979; 1(3):309-15. PubMed ID: 399241 [No Abstract] [Full Text] [Related]
12. The effect of clinical prostacyclin infusions in advanced arterial disease on platelet function and plasma 6-keto PGF1 alpha levels. Machin SJ; Chamone DA; Defreyn G; Vermylen J Br J Haematol; 1981 Mar; 47(3):413-22. PubMed ID: 7006673 [TBL] [Abstract][Full Text] [Related]
13. Increased platelet activity after termination of prostacyclin infusion into man. Dembinska-Kiec A; Zmuda A; Grodzinska L; Bieron K; Basista M; Kedzior A; Kostka-Trabka E; Telesz E; Zelazny T Prostaglandins; 1981 May; 21(5):827-32. PubMed ID: 6803307 [TBL] [Abstract][Full Text] [Related]
14. Lack of effect of ischemia and dipyridamole on prostacyclin production in arteriosclerosis obliterans. Viinikka L; Kärkölä P; Pokela R; Ylikorkala O Prostaglandins; 1981 May; 21(5):821-6. PubMed ID: 7041195 [TBL] [Abstract][Full Text] [Related]
15. Effect of prostacyclin (PGI2) on platelets and fibrinolytic activity in patients with arteriosclerosis obliterans. Dembińska-Kieć A; Kostka-Trabka E; Zumda A; Byrska-Danek A; Bierón K; Grodzińska L; Kedzior A; Zelazny T Pharmacol Res Commun; 1982 Jun; 14(6):485-98. PubMed ID: 6750655 [No Abstract] [Full Text] [Related]
16. Thromboxane B2, 6-keto-PGF1 alpha, PGE2, PGF2 alpha, and PGA1 plasma levels in arteriosclerosis obliterans: relationship to clinical manifestations, risk factors, and arterial pathoanatomy. Jouve R; Rolland PH; Delboy C; Mercier C Am Heart J; 1984 Jan; 107(1):45-52. PubMed ID: 6581715 [TBL] [Abstract][Full Text] [Related]
17. Prostacyclin (PGI2) effects on anterior pituitary hormones in the rat in vivo. Kimball FA; Porteus SE; Kirton KT; Frielink RD; Creasy DM; Dayan AD Prostaglandins; 1979 Sep; 18(3):377-85. PubMed ID: 394197 [TBL] [Abstract][Full Text] [Related]
18. Effect of infusion of PGI-2, 6-keto-PGF-1 alpha and PGF-2 alpha on luteal function in the pregnant rat. Henderson KM; Willcox DL; Bruce NW J Reprod Fertil; 1983 Sep; 69(1):11-6. PubMed ID: 6350568 [TBL] [Abstract][Full Text] [Related]
19. Prostacyclin and pathogenesis of hemodynamic abnormalities of diabetic ketoacidosis in rats. Quyyumi AA; Iaffaldano R; Guerrero JL; Ryan CA; Powell WJ; Axelrod L Diabetes; 1989 Dec; 38(12):1585-94. PubMed ID: 2511053 [TBL] [Abstract][Full Text] [Related]
20. Prostacyclin potently resorbs bone in vitro. Bennett A; Edwards D; Ali NN; Auger D; Harris M Adv Prostaglandin Thromboxane Res; 1980; 6():547-8. PubMed ID: 6992541 [No Abstract] [Full Text] [Related] [Next] [New Search]